Active And Progressive Disease

SAN DIEGO — Black individuals with MS were more disabled than white patients, with higher rates of ambulatory assistance, hospitalization and vision loss driving the difference, per a poster at ACTRIMS 2023.

The European Commission has approved the subcutaneous formulation of Celltrion’s infliximab biosimilar for adult patients with active rheumatoid arthritis who have had an inadequate response to a prior DMARD, as well as patients with severe, active and progressive disease not previously treated with DMARDs, according to a manufacturer press release.